Our portfolio

To date, CEPI has established multiple partnership agreements, reflecting a potential investment of up to $480 million. Through these collaborations, we're supporting the development of a wide range of vaccine candidates and platform technologies.

CEPI is also funding seven programmes which aim to rapidly advance the development of vaccine candidates against the COVID-19 virus.

PRODUCT DEVELOPERS
  • All
  • Colorado State University
  • CureVac
  • IDT Biologika
  • Imperial College London
  • Inovio Pharmaceuticals
  • Institut Pasteur, Themis Bioscience, University of Pittsburgh
  • International AIDS Vaccine Initiative
  • Janssen Vaccines & University of Oxford
  • Moderna, Inc.
  • Novavax, Inc.
  • Profectus Biosciences, Emergent Biosolutions & PATH
  • Public Health Vaccines
  • The University of Hong Kong
  • Themis Bioscience
  • University of Oxford
  • University of Queensland
  • University of Tokyo
  • Valneva SE
  • Wageningen Bioveterinary Research
DISEASE
  • All
  • Chikungunya
  • COVID-19
  • Lassa virus
  • Marburg virus
  • MERS coronavirus
  • Nipah virus
  • Rift Valley Fever
VACCINE TYPE
  • All
  • ChAdOx1
  • Live attenuated vaccine
  • Measles vector
  • Nucleic acid
  • Recombinant protein
  • Recombinant protein nanoparticle technology
  • Recombinant viral vector
PHASE
  • All
  • Phase 1
  • Phase 2
  • Phase 3
  • Preclinical
{{ mob.finishButton }}
Filter by product developers:
Filter by disease:
Filter by vaccine type:
Filter by phase:

{{ dev['funding_title'] }}

{{ dev['funding'] }}

{{ d['disease'] }}
{{ d['vaccine_type'] }}
{{ d['trial_title'] }}
{{ d['trial'] }}
{{ d['phase'] }}
?
?

{{ d['description'] }}

N/A
No result